M. H. Carnegie & Co.
VC Fund
Paddington, Australia
M. H. Carnegie & Co. is a VC fund in Paddington focused on Health Care and Medical Device. M.H. Carnegie & Co. was launched by Mark Carnegie in 2010 with total equity commitments of $132 million to capitalise on the post financial crisis environment in the Australian market for smaller alternative investment opportunities. M.H. Carnegie & Co. was launched with a focus and expertise in expansion capital, as well as operating realestate.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 23%
Last updated:
For AI agents: llms.txt
Industries M. H. Carnegie & Co. invests in
Stages M. H. Carnegie & Co. invests in
Countries M. H. Carnegie & Co. invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $7M–$7M
- Series A
- $15M–$20M
- Series B
- $21M–$39M
Investment Focus
Industry
- Health Care 3 (23%)
- Medical Device 3 (23%)
- Medical 2 (15%)
- eSports 1 (8%)
- Blockchain 1 (8%)
Stage
- Series B 2 (15%)
- Seed 1 (8%)
- Series A 1 (8%)
- Series C 1 (8%)
- Series D 1 (8%)
Country
- United States 3 (23%)
- Panama 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Mark Carnegie
Founder
|
Founder | Total investments: 6 | Find email | |
Kate Thompson
Partner
|
Partner | Total investments: 0 | Find email | |
Matthew Beach
Partner
|
Partner | Total investments: 0 | Find email | |
Trevor Moody
Managing Director
|
Managing Director | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cardiac Dimensions
|
Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $53M / Series E / Mar 20, 2025 | |
|
Cardiac Dimensions
|
Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $35M / Series D / Jan 05, 2023 | |
Ignite Tournaments
|
esports, mobile games, streaming, crypto, blockchain, and tournament organization | $7M / Mar 03, 2022 | |
|
Ignite Tournaments
|
esports, mobile games, streaming, crypto, blockchain, and tournament organization | $7M / Seed / Mar 03, 2022 | |
|
Ignite Tournaments
|
esports, mobile games, streaming, crypto, blockchain, and tournament organization | $7M / Seed / Mar 03, 2022 | |
|
Cardiac Dimensions
|
Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $17.5M / Series C / Sep 29, 2020 | |
EBR Systems
|
EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias. | $30M / Private Equity / Aug 27, 2019 | |
|
Cardiac Dimensions
|
Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $39M / Series B / Apr 26, 2018 | |
Simplify Medical
|
Simplify Medical designs, develops, and manufactures cervical artificial discs for use in the spine. It offers an MRI compatible motion preserving artificial cervical disc that is used to treat single level symptomatic cervical disc disease.The company provides its products for skeletally mature patients for reconstruction of the disc at onelevel from C3-C7 following single-level discectomy for intractable radiculopathy, such as arm pain or a neurological deficit.Simplify Medical was founded in 2015 and is based in Mountain View, California. | $23M / Series B / Feb 09, 2018 | |
|
EBR Systems
|
EBR Systems, Inc. is an early-stage development venture pursuing novel approaches in cardiac rhythm management. EBR Systems develops devices for the treatment of cardiac arrhythmias. | $50M / Private Equity / Nov 14, 2017 | |
| See all 13 investments → | |||
Co-Investors
Lumira Ventures
6 deals together
Arboretum Ventures
4 deals together
Hostplus
4 deals together
EQT Life Sciences
4 deals together
Animoca Brands
3 deals together
Aperture Venture Partners
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does M. H. Carnegie & Co. invest in?
M. H. Carnegie & Co. invests primarily in Health Care, Medical Device and Medical startups, most often at Series B and Seed stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is M. H. Carnegie & Co.'s check size?
M. H. Carnegie & Co. typically joins rounds of $7M–$7M at Seed, $15M–$20M at Series A and $21M–$39M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds M. H. Carnegie & Co. participates in.
How do I contact M. H. Carnegie & Co.?
Public channels for M. H. Carnegie & Co. include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at M. H. Carnegie & Co.?
The team at M. H. Carnegie & Co. includes Mark Carnegie (Founder), Kate Thompson (Partner) and Matthew Beach (Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
